41 results on '"Riemekasten, G"'
Search Results
2. AB1196 BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN SUBJECTS WITH ILD IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
3. POS0832 IMMUNOSUPPRESSION VERSUS COMBINATION OF IMMUNOSUPPRESSION AND ORAL GLUCOCORTICOIDS FOR SKIN FIBROSIS IN EARLY DIFFUSE SYSTEMIC SCLEROSIS PATIENTS. A TARGET TRIAL EMULATION STUDY FROM THE EUSTAR DATABASE
4. OP0013 ANTI-Ro/SSA ANTIBODIES ARE PREDICTIVE OF A MORE SEVERE LUNG INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR HDATABASE
5. AB0919 DYNAMIC OPTICAL COHERENCE TOMOGRAPHY MIGHT BE A VALUABLE TOOL TO ASSESS THERAPEUTIC EFFICACY OF VASOACTIVE THERAPY IN SYSTEMIC SCLEROSIS
6. OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS
7. POS0150 AUTOANTIBODIES AGAINST FIBROBLAST GROWTH FACTOR (FGF-2), PLACENTAL GROWTH FACTOR (PLGF) AND BETA-ADRENERGIC RECEPTOR 1 (ADRB1) IN AN ALTERED NETWORK OF AUTOANTIBODIES IN SYSTEMIC SCLEROSIS
8. POS0875 AUTOANTIBODIES DIRECTED TO G-PROTEIN COUPLED RECEPTORS CORRELATE WITH DISEASE ACTIVITY SCORES IN PATIENTS WITH PSORIATIC ARTHRITIS
9. POS0121 COMPARISON OF FOUR RISK STRATIFICATION MODELS FOR PREDICTION OF MORTALITY IN SSc-PAH IN THE EUSTAR COHORT
10. AB0157 SYNERGISTIC EFFECT OF AT1R-AUTOANTIBODIES AND EXTRACELLULAR VESICLES IN SSC PATHOGENESIS
11. POS1161 RITUXIMAB VS. COMBINATION OF RITUXIMAB AND CYCLOPHOSPHAMIDE INDUCTION THERAPY FOR ANCA-ASSOCIATED VASCULITIS: A RETROSPECTIVE STUDY
12. S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial
13. Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from EUSTAR
14. Progressive interstitial lung disease is frequent also in late disease stages in systemic sclerosis patients from EUSTAR
15. Risk stratification approaches perform differently in SSc-associated PAH in EUSTAR
16. Does anti-acid treatment influence disease progression in SSc-ILD? Data form the German SSc-network
17. Long term outcomes of immunmodulatory drugs in SSc-ILD – data rom the German SSc network
18. Prediction and Frequency of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the World’s Largest Database of Patients with Systemic Sclerosis (EUSTAR)
19. Preservation of Lung Function Observed in a Phase 3 Randomized Controlled Trial of Tocilizumab for the Treatment of Early Systemic Sclerosis
20. Predictors for the Development of Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) - Data from the German SSc-Network
21. Feasibility and Efficacy of Cohort Enrichment for Progressive Lung Fibrosis in Systemic Sclerosis - a EUSTAR Database Analysis
22. P134/O32 Selective expansion of a thymic-derived and functionally competent regulatory T cell population by low-dose IL-2 therapy in patients with refractory SLE
23. Significance of pulmonary involvement in systemic sclerosis (SSc) – data form the German SSc-network
24. SAT0506 Ssc in older age: frequent and with a different phenotype. data of the german network for systemic sclerosis
25. SAT0508 Ace-inhibitors in arterial hypertension in ssc patients display a risk factor for scleroderma renal crisis – a eustar analysis
26. AB0809 A new score to predict digital ulcers combining clinical data, imaging and patient history in systemic sclerosis
27. AB0035 A physiological network of igg autoantibodies targeting g protein coupled receptors
28. THU0409 Management of systemic sclerosis (SSC) related digital ulcers (DU) in expert tertiary centres: results from the analysis of the multicentre observational real-life desscipher/eustar study
29. OP0005 Patterns of 31 new autoantibodies against g protein-coupled receptors and growth factors in systemic sclerosis can be described by latent factors
30. FRI0405 A novel animal model for systemic sclerosis induced by immunisation of angiotensin ii receptor 1
31. PS5:101 Nuclear antigen-reactive cd4+ t cells are expanded in active sle, correlate with disease activity, invade target organs such as the kidneys, and outnumber their regulatory counterparts
32. AB0181 Diffusing capacity and clinical characteristics of patients with systemic sclerosis – data from the german network for systemic sclerosis
33. SAT0320 SSC- IGG effects are mediated through distinct pathways in THP-1 cells
34. AB0175 Inhibitory effect of endothelin-1 type a receptor antagonists on migration of neutrophils and tumour cells
35. SAT0011 The activation of muscarinic acetylcholine receptors influences the ontogeny of neutrophils
36. SAT0618 Disturbances of the acral perfusion detected by fluorescence optical imaging are associated with the development of ischemic complications in patients with systemic sclerosis
37. AB0169 Evaluation of frequency and type of physical therapy in more than 3400 patients with systemic sclerosis
38. AB0003 A mif promoter polymorphism is associated with the susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis patients
39. THU0006 Trans-ethnic meta-analysis of genome-wide association studies identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis
40. SAT0333 Prevalence of sarcopenia in patients with systemic sclerosis according to the revised criteria of the european working group on sarcopenia in older people
41. OP0076 Kidneys of autoimmune nzb/w mice contain long-lived pc
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.